MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B
Shots: MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. The transaction is expected to close in Q3’21 The acquisition will bolster Morphosys’ position in hematology-oncology & accelerates growth strategy with the addition of Constellation’s Pelabresib (CPI-0610) & CPI-0209 Additionally, […]